Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Chandra Bhagat Pharma's ROE % for the quarter that ended in Mar. 2026 was 16.35%. Chandra Bhagat Pharma's PB Ratio for the quarter that ended in Mar. 2026 was 0.68.
Chandra Bhagat Pharma's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was 24.04%.
Chandra Bhagat Pharma ROE % Adjusted to Book Value Related Terms
Chandra Bhagat Pharma ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for Chandra Bhagat Pharma's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chandra Bhagat Pharma ROE % Adjusted to Book Value Chart
BOM:542934 vs MCK, CAH, COR: ROE % Adjusted to Book Value Comparison
For the Medical Distribution subindustry, Chandra Bhagat Pharma's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chandra Bhagat Pharma ROE % Adjusted to Book Value vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Chandra Bhagat Pharma's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Chandra Bhagat Pharma's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of 24.04% mean?
Chandra Bhagat Pharma (BOM:542934) has a ROE % Adjusted to Book Value of 24.04% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Chandra Bhagat Pharma and its competitors.
Is Chandra Bhagat Pharma's ROE % Adjusted to Book Value too high?
Chandra Bhagat Pharma's current ROE % Adjusted to Book Value is 24.04%. Overall, Chandra Bhagat Pharma has a GF Score™ of 65/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Chandra Bhagat Pharma's ROE % Adjusted to Book Value compare to MCK and CAH?
Chandra Bhagat Pharma's ROE % Adjusted to Book Value of 24.04% can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Medical Distribution company?
A good ROE % Adjusted to Book Value depends on the Medical Distribution industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Chandra Bhagat Pharma and its competitors. Chandra Bhagat Pharma's current ROE % Adjusted to Book Value is 24.04%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chandra Bhagat Pharma stock overvalued right now?
Based on GuruFocus' analysis, Chandra Bhagat Pharma (BOM:542934) is currently considered Possible Value Trap. The stock's GF Value™ is ₹70.18, compared to a current price of ₹33.00 — trading 53% below its estimated fair value. The current ROE % Adjusted to Book Value is 24.04%. Chandra Bhagat Pharma's overall GF Score™ is 65/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Chandra Bhagat Pharma (BOM:542934), the current ROE % Adjusted to Book Value is 24.04% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chandra Bhagat Pharma (BOM:542934) Overvalued in 2026?
Based on GuruFocus' analysis, Chandra Bhagat Pharma stock appears to be undervalued.
The current stock price of ₹33.00 is trading 53% below its estimated GF Value™ of ₹70.18.
GuruFocus considers Chandra Bhagat Pharma to be Possible Value Trap.
Key valuation signals for BOM:542934:
ROE % Adjusted to Book Value: 24.04%
GF Value™: ₹70.18 vs. price of ₹33.00 (53% below fair value)
No single metric tells the full story. See the BOM:542934 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chandra Bhagat Pharma Ltd is a pharmaceutical company marketing pharmaceutical, critical care, and health care products across the globe. The company deals in many categories of pharmaceutical products like anticancer, cardiovascular, anti-infective, etc. It offers various forms of pharmaceutical products, like oral solids. tablets, capsules, liquid orals, syrup suspension, injections, liquid, powder, etc. Additionally, the company is also engaged in promoting and marketing of Active Pharmaceutical Ingredients (API's) in India.
65GF Score
Get the complete analysis for BOM:542934
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:542934 has been successfully added to your 
